Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

343 ARTÍCULOS , VIENDO DEL 166 AL 180

Alzheimer's disease and epigenetic diet

Sezgin Z, Dincer Y.

Neurochem Int. 2014 Dec;78:105-16. doi: 10.1016/j.neuint.2014.09.012. Epub 2014 Oct 5.

Advances in recent patent and clinical trial drug development for Alzheimer's disease

Liu H, Wang L, Su W, Xie XQ.

Pharm Pat Anal. 2014 Jul;3(4):429-47. doi: 10.4155/ppa.14.22.

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease

Lawlor B, Kennelly S, O'Dwyer S, Cregg F, Walsh C, Coen R, Kenny RA, Howard R, Murphy C, Adams J, Daly L, Segurado R, Gaynor S, Crawford F, Mullan M, Lucca U, Banzi R, Pasquier F, Breuilh L, Riepe M, Kalman J, Wallin A, Borjesson A, Molloy W, Tsolaki M, Olde Rikkert M.

BMJ Open. 2014 Oct 9;4(10):e006364. doi: 10.1136/bmjopen-2014-006364.

Dietary polyphenols for treatment of Alzheimer's disease--future research and development

Malar DS, Devi KP.

Curr Pharm Biotechnol. 2014;15(4):330-42. doi: 10.2174/1389201015666140813122703.

Stem cell treatment for Alzheimer's disease

Li M, Guo K, Ikehara S.

Int J Mol Sci. 2014 Oct 23;15(10):19226-38. doi: 10.3390/ijms151019226.

Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease

Ahmad MZ, Ahmad J, Amin S, Rahman M, Anwar M, Mallick N, Ahmad FJ, Rahman Z, Kamal MA, Akhter S.

CNS Neurol Disord Drug Targets. 2014;13(8):1315-24. doi: 10.2174/1871527313666141023100618.

[Economic impact of Alzheimer's Disease in Brazil: is it possible to improve care and minimize costs?]

Gutierrez BA, Silva HS, Guimarães C, Campino AC.

Cien Saude Colet. 2014 Nov;19(11):4479-86. doi: 10.1590/1413-812320141911.03562013.

FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease

Paroni G, Seripa D, Fontana A, D'Onofrio G, Gravina C, Urbano M, Cascavilla L, Pellegrini F, Greco A, Pilotto A.

Clin Interv Aging. 2014 Oct 21;9:1783-91. doi: 10.2147/CIA.S64758. eCollection 2014.

Structure and mechanism of action of tau aggregation inhibitors

Cisek K, Cooper GL, Huseby CJ, Kuret J.

Curr Alzheimer Res. 2014;11(10):918-27. doi: 10.2174/1567205011666141107150331.

Epigenetic nutraceutical diets in Alzheimer's disease

Davinelli S, Calabrese V, Zella D, Scapagnini G.

J Nutr Health Aging. 2014 Nov;18(9):800-5. doi: 10.1007/s12603-014-0552-y.

The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer's Disease

Nagase H, Nakayama K.

Curr Drug Discov Technol. 2014;11(4):243-58. doi: 10.2174/1570163811666141121101358.

Amyloid beta peptide immunotherapy in Alzheimer disease

Delrieu J, Ousset PJ, Voisin T, Vellas B.

Rev Neurol (Paris). 2014 Dec;170(12):739-48. doi: 10.1016/j.neurol.2014.10.003. Epub 2014 Nov 6.

Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?

Loeffler DA.

J Neuroinflammation. 2014 Dec 5;11:198. doi: 10.1186/s12974-014-0198-z.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias